About: Resistance Prediction in AML: Analysis of 4,601 Patients from MRC/NCRI, HOVON/SAKK, SWOG, and MD Anderson Cancer Center

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Resistance Prediction in AML: Analysis of 4,601 Patients from MRC/NCRI, HOVON/SAKK, SWOG, and MD Anderson Cancer Center Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Resistance Prediction in AML: Analysis of 4,601 Patients from MRC/NCRI, HOVON/SAKK, SWOG, and MD Anderson Cancer Center
Creator	Othus, Megan Evans, Anna Löwenberg, Bob Pabst, Thomas Ravandi, Farhad Vekemans, Marie-Christiane Estey, Elihu Appelbaum, Frederick Burnett, Alan Hills, Robert Kantarjian, Hagop Ossenkoppele, Gert Pierce, Sherry Walter, Roland
source	PMC
abstract	Therapeutic resistance remains the principal problem in acute myeloid leukemia (AML). We used area under receiver operator characteristic curves (AUC) to quantify our ability to predict therapeutic resistance in individual patients where AUC=1.0 denotes perfect prediction and AUC=0.5 denotes a coin flip, using data from 4,601 patients with newly diagnosed AML given induction therapy with 3+7 or more intense standard regimens in MRC/NCRI, HOVON, SWOG, and MD Anderson Cancer Center studies. Age, performance status, white blood cell count, secondary disease, cytogenetic risk, and FLT3-ITD/NPM1 mutation status were each independently associated with failure to achieve complete remission despite no early death (“primary refractoriness”). However, the AUC of a bootstrap-corrected multivariable model predicting this outcome was only 0.78, indicating only fair predictive ability. Removal of FLT3-ITD and NPM1 information only slightly decreased the AUC (0.76). Prediction of resistance, defined as primary refractoriness or short relapse-free survival (RFS), was even more difficult. Our ability to forecast resistance based on routinely available pre-treatment covariates provides a rationale for continued randomization between standard and new therapies and supports further examination of genetic and post-treatment data to optimize resistance prediction in AML.
has issue date	2014-08-12(xsd:dateTime)
bibo:doi	10.1038/leu.2014.242
bibo:pmid	25113226
has license	no-cc
sha1sum (hex)	2e6b763befef8fc1df4868231c49171d57793e8a
schema:url	https://doi.org/10.1038/leu.2014.242
resource representing a document's title	Resistance Prediction in AML: Analysis of 4,601 Patients from MRC/NCRI, HOVON/SAKK, SWOG, and MD Anderson Cancer Center
has PubMed Central identifier	PMC4318722
has PubMed identifier	25113226
schema:publication	Leukemia
resource representing a document's body	covid:2e6b763befef8fc1df4868231c49171d57793e8a#body_text
is schema:about of	named entity 'SWOG' named entity 'RESISTANCE' named entity 'OUR' named entity 'ASSOCIATED WITH' named entity 'RESISTANCE' named entity 'TREATMENT DATA' named entity 'COMPLETE REMISSION' named entity 'USED' named entity '2B7' named entity 'DATA' named entity 'MUTATION' named entity 'SECONDARY DISEASE' named entity 'PREDICTING' named entity 'DOCUMENTS' named entity 'CORRECTED' named entity 'MODEL' named entity 'AGE' named entity 'POST-TREATMENT' covid:arg/2e6b763befef8fc1df4868231c49171d57793e8a named entity 'AML' named entity 'CYTOGENETIC' named entity 'MD ANDERSON CANCER CENTER' named entity 'REFRACTORINESS' named entity 'REMOVAL' named entity 'OUTCOME' named entity 'PREDICTIVE' named entity 'STANDARD' named entity 'USING' named entity 'PUBLIC' named entity 'MRC' named entity 'PREDICTION' named entity 'ACCESS' named entity 'HHS' named entity 'ANALYSIS' named entity 'PATIENTS' named entity 'FLIP' named entity 'THERAPIES' named entity 'PRIMARY' named entity 'AUC' named entity 'RISK' named entity 'BASED' named entity 'OPERATOR' named entity 'STUDIES' named entity 'ACUTE MYELOID LEUKEMIA' named entity 'PREDICTION' named entity 'WHERE' named entity 'COPY' named entity 'AML' named entity 'RELAPSE-FREE SURVIVAL' named entity 'COIN' named entity 'FAIR' named entity 'USERS' named entity 'PATIENTS' named entity 'SUBJECT' named entity 'USE' named entity 'GIVEN' named entity 'RANDOMIZATION' named entity 'RATIONALE' named entity 'INTENSE' named entity 'RESEARCH' named entity 'QUANTIFY' named entity 'PROVIDES' named entity 'NPM1' named entity 'DIFFICULT' named entity 'MD ANDERSON CANCER CENTER' named entity 'REGIMENS' named entity 'OPTIMIZE' named entity 'DECREASED'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software